英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：


请选择你想看的字典辞典：
单词字典翻译
farcer查看　farcer　在百度字典中的解释百度英翻中〔查看〕
farcer查看　farcer　在Google字典中的解释Google英翻中〔查看〕
farcer查看　farcer　在Yahoo字典中的解释Yahoo英翻中〔查看〕

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • UC Irvine Solid Tumor Trial: NVL-655 in Patients With Advanced NSCLC . . .
    This Solid Tumor and Non-Small Cell Lung Cancer study at UC Irvine is now recruiting people ages 12 years and up Skip to main content and evaluate the antitumor activity in patients with advanced ALK- positive (ALK+) NSCLC and other solid tumors Phase 1 will evaluate the overall safety and tolerability of NVL-655 and will determine the
  • Ph I II Study of NVL-655 Patients with Advanced NSCLC and . . . - UCI Health
    UCI Specialty Area: Cancer Principal Investigator: Misako Nagasaka Official Title Lung Melanoma skin Mycosis Fungoides Other Digestive Organ Other Endocrine System (RP2D), and evaluate the antitumor activity in patients with advanced ALK- positive (ALK+) NSCLC and other solid tumors Phase 1 will determine the RP2D and, if
  • Final Overall Survival and Long-Term Safety of Lorlatinib in Patients . . .
    Introduction: Lorlatinib is a potent, brain-penetrant, third-generation inhibitor of anaplastic lymphoma kinase (ALK) and ROS1 tyrosine kinases with broad coverage of ALK resistance mutations We present the overall survival (OS) and long-term safety of lorlatinib in patients with advanced ALK-positive NSCLC from the final analyses of the pivotal phase 2 study
  • Lung Clinical Trials - University of California, Irvine
    Advanced Non-Small Cell Lung Cancer EGFR Lung Clinical Trials Ou Jenny Choe UCI 21-53: A Phase Ia Ib Study of LY3537982 in Patients with Activity of TPX-0005 in Patients with Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1) ROS1, NTRK1, NTRK2, NTRK3
  • Lorlatinib Versus Crizotinib in Patients With Advanced ALK-Positive Non . . .
    Anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) are the standard first-line therapy recommended for patients with ALK-positive non–small cell lung cancer (NSCLC) 1 Lorlatinib is a brain-penetrant, third-generation ALK TKI that has greater coverage of ALK resistance mutations than second-generation ALK inhibitors 2,3 In the phase III CROWN study, lorlatinib showed
  • University of California Health Non-Small Cell Lung Cancer Clinical . . .
    Do you qualify for these Non-Small Cell Lung Cancer studies? We offer 108 options at UC Irvine UCSF (OS), and clinical benefit rate (CBR) of NVL-655 in patients with advanced ALK-positive NSCLC and other solid tumors at UC Davis UC Irvine NX-1607 in Adults With Advanced Malignancies
  • Lorlatinib Demonstrates “Fantastic” PFS Results in Advanced ALK+ NSCLC
    Investigators of the CROWN trial highlighted that lorlatinib (Lorbrena) reduced the risk of disease progression or death vs crizotinib (Xalkori) among patients with advanced non–small cell lung cancer (NSCLC) harboring ALK-positive disease (HR, 0 19; 95% CI, 0 13-0 27)
  • Biomarker-Specific Survival and Cost for Advanced NSCLC
    Key Points Question What are the survival and medication cost for advanced non–small cell lung cancer by biomarker status? Findings In this cohort study using data from 26 635 patients, the median overall survival was 39 9 months for ALK rearrangement, 27 0 months for EGFR variation, and 12 to 16 months for 3 programmed cell death 1 ligand 1 (PD-L1) groups
  • Non-Small Cell Lung Cancer clinical trials at UC Irvine
    Non-Small Cell Lung Cancer clinical trials at UC Irvine 47 in progress, 22 open to eligible people Showing trials for and evaluate the antitumor activity in patients with advanced ALK- positive (ALK+) NSCLC and other solid tumors Phase 1 will evaluate the overall safety and tolerability of NVL-655 and will determine the RP2D and, if
  • First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer
    Camidge DR, Kim HR, Ahn M-J, et al Brigatinib versus crizotinib in advanced ALK inhibitor-naive ALK-positive non-small cell lung cancer: second interim analysis of the Phase III ALTA-1L trial





中文字典-英文字典  2005-2009